Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Equity Ratio (2016 - 2023)

Rapid Therapeutic Science Laboratories' Equity Ratio history spans 8 years, with the latest figure at 1.32 for Q2 2023.

  • For Q2 2023, Equity Ratio fell 9.92% year-over-year to 1.32; the TTM value through Jun 2023 reached 1.32, down 9.92%, while the annual FY2022 figure was 1.39, 121.85% down from the prior year.
  • Equity Ratio for Q2 2023 was 1.32 at Rapid Therapeutic Science Laboratories, up from 1.39 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.76 in Q1 2021 and bottomed at 2375.18 in Q1 2019.
  • The 5-year median for Equity Ratio is 1.34 (2022), against an average of 261.53.
  • The largest YoY upside for Equity Ratio was 124.74% in 2021 against a maximum downside of 8386.58% in 2021.
  • A 5-year view of Equity Ratio shows it stood at 3.01 in 2019, then soared by 99.75% to 0.01 in 2020, then crashed by 8386.58% to 0.63 in 2021, then plummeted by 121.85% to 1.39 in 2022, then grew by 5.23% to 1.32 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Equity Ratio are 1.32 (Q2 2023), 1.39 (Q1 2023), and 1.39 (Q4 2022).